恩替卡韦治疗乙型肝炎病毒感染患者的临床疗效及对总胆红素及凝血酶原时间的影响分析  

Clinical efficacy of entecavir in the treatment of patients with hepatitis B virus infection and its impact on total bilirubin and prothrombin time

作　　者：徐雷 狄龙 李文臣 XU Lei;DI Long;LI Wen-chen(Department of Infectious Diseases,Xuecheng District People's Hospital,Zaozhuang 277000,China)

机构地区：[1]枣庄市薛城区人民医院感染性疾病科,277000

出　　处：《中国实用医药》2025年第4期103-106,共4页China Practical Medicine

摘　　要：目的观察乙型肝炎病毒感染患者采取恩替卡韦治疗的临床疗效,并分析其对患者总胆红素及凝血酶原时间的影响。方法选取乙型肝炎病毒感染患者60例作为此次研究对象,根据治疗方案的不同将其分成对照组(30例)和观察组(30例)。对照组采取常规治疗,观察组在对照组基础上加入恩替卡韦治疗。比较两组临床疗效,治疗前后肝功能(总胆红素、天冬氨酸氨基转移酶、丙氨酸氨基转移酶)、凝血功能(凝血酶原时间、抗凝血酶Ⅲ、纤维蛋白原)、乙型肝炎病毒学[乙型肝炎e抗体(HBeAb)、乙型肝炎表面抗原(HBsAg)、乙型肝炎e抗原(HBeAg)]、生存质量。结果治疗总有效率比较,观察组(93.33%)显著比对照组(70.00%)更高(P<0.05)。总胆红素、天冬氨酸氨基转移酶、丙氨酸氨基转移酶水平比较,两组治疗后显著比治疗前更低,且观察组(21.17±5.34)μmol/L、(59.94±9.25)U/L、(57.90±6.41)U/L低于对照组的(26.48±6.92)μmol/L、(70.21±8.70)U/L、(68.01±7.53)U/L(P<0.05)。凝血酶原时间、抗凝血酶Ⅲ、纤维蛋白原水平比较,两组治疗后显著比治疗前更优,且观察组(19.92±1.08)s、(73.46±12.09)%、(6.40±0.70)g/L优于对照组的(21.84±1.57)s、(65.10±11.91)%、(7.32±0.81)g/L(P<0.05)。两组治疗后HBeAb水平显著比治疗前更低,且观察组(11.40±1.37)S/CO低于对照组的(12.50±2.49)S/CO(P<0.05);两组治疗前后HBsAg、HBeAg水平组间组内比较不存在统计学意义(P>0.05)。疲乏状态、睡眠、社交质量、健康总体测评评分比较,两组治疗后显著比治疗前更高,且观察组(59.52±3.06)、(57.76±2.18)、(63.80±3.37)、(60.36±2.17)分高于对照组的(52.90±4.86)、(51.54±3.09)、(56.15±5.76)、(54.89±3.01)分(P<0.05)。结论恩替卡韦能够提高乙型肝炎病毒感染患者的临床治疗效果,可能与其能够改善患者总胆红素、凝血酶原时间等机制有关。Objective To observe the clinical efficacy of entecavir in the treatment of patients with hepatitis B virus infection and analyze its impact on total bilirubin and prothrombin time of patients.Methods 60 patients infected with hepatitis B virus were selected as the subjects of this study,and were divided into control group(30 cases)and observation group(30 cases)according to different treatment plans.The control group received conventional treatment,and the observation group received entecavir treatment on the basis of the control group.Comparison was made on clinical efficacy,liver function(total bilirubin,aspartate aminotransferase,alanine aminotransferase),coagulation function(prothrombin time,antithrombinⅢ,fibrinogen),hepatitis B virology[Hepatitis B virus e antibody(HBeAb),hepatitis B surface antigen(HBsAg),hepatitis Be antigen(HBeAg)]and quality of life before and after treatment.Results The total effective rate of the observation group(93.33%)was significantly higher than that of the control group(70.00%)(P<0.05).After treatment,the levels of total bilirubin,aspartate aminotransferase,and alanine aminotransferase in both groups were significantly lower than those before treatment;the above indicators were(21.17±5.34)μmol/L,(59.94±9.25)U/L,and(57.90±6.41)U/L in the observation group,which were lower than(26.48±6.92)μmol/L,(70.21±8.70)U/L,and(68.01±7.53)U/L in the control group(P<0.05).After treatment,the prothrombin time,antithrombinⅢand fibrinogen levels in both groups were significantly better than those before treatment;the above indicators were(19.92±1.08)s,(73.46±12.09)%and(6.40±0.70)g/L in the observation group,which were better than(21.84±1.57)s,(65.10±11.91)%and(7.32±0.81)g/L in the control group(P<0.05).After treatment,the HBeAb level in both groups was significantly lower than that before treatment,and the observation group had a lower than(12.50±2.49)S/CO in the control group(P<0.05).There was no statistical significance in the level of HBsAg and HBeAg between the two groups be

关 键 词：恩替卡韦 乙型肝炎病毒感染 临床疗效 总胆红素 凝血酶原时间 

分 类 号：R51[医药卫生—内科学]